Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BMRA
Biomerica, Inc. (BMRA) EV/Sales
As of 16 October 2026, Biomerica, Inc. (BMRA) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.1× (August 2024) to 30.1× (March 2020); the current reading is higher than 11% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.3× | 23.32% |
| FY2025 | 1.0× | (1.71%) |
| FY2024 | 1.0× | (43.03%) |
| FY2023 | 1.8× | (11.06%) |
| FY2022 | 2.0× | (62.73%) |
| FY2021 | 5.5× | (34.59%) |
| FY2020 | 8.4× | 116.80% |
| FY2019 | 3.9× | (36.33%) |
| FY2018 | 6.1× | 78.85% |
| FY2017 | 3.4× | 68.64% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| May 2026 | 1.3× | 13.34% |
| Feb 2026 | 1.1× | 22.12% |
| Nov 2025 | 0.9× | (9.22%) |
| Aug 2025 | 1.0× | (1.85%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AEMD Aethlon Medical, Inc. compare | −2.8× |
| TNON Tenon Medical, Inc. compare | −0.1× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| NMTC NeuroOne Medical Technologies Corporation compare | 0.7× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| BMRA Biomerica, Inc. | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)